Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
Eric BouffetJordan R HansfordMaria Luisa GarrèJunichi HaraAshley Plant-FoxIsabelle AertsFranco LocatelliJasper van der LugtLudmila PapushaFelix SahmUri TaboriKenneth J CohenRoger J PackerOlaf WittLarissa SandalicAna Bento Pereira da SilvaMark RussoDarren R HargravePublished in: The New England journal of medicine (2023)
V600 mutations, dabrafenib plus trametinib resulted in significantly more responses, longer progression-free survival, and a better safety profile than standard chemotherapy as first-line therapy. (Funded by Novartis; ClinicalTrials.gov number, NCT02684058.).